Literature DB >> 12770952

Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.

David J Behm1, Stephen M Harrison, Zhaohui Ao, Kristeen Maniscalco, Susan J Pickering, Evelyn V Grau, Tina N Woods, Robert W Coatney, Christopher P A Doe, Robert N Willette, Douglas G Johns, Stephen A Douglas.   

Abstract

1 Urotensin-II (U-II) is among the most potent mammalian vasoconstrictors identified and may play a role in the aetiology of essential hypertension. Currently, only one mouse U-II receptor (UT) gene has been cloned. It is postulated that this protein is solely responsible for mediating U-II-induced vasoconstriction. 2 This hypothesis has been investigated in the present study, which assessed basal haemodynamics and vascular reactivity to hU-II in wild-type (UT((+/+))) and UT receptor knockout (UT((-/-))) mice. 3 Basal left ventricular end-diastolic and end-systolic volumes/pressures, stroke volumes, mean arterial blood pressures, heart rates, cardiac outputs and ejection fractions in UT((+/+)) mice and in UT((-/-)) mice were similar. 4 Relative to UT((+/+)) mouse isolated thoracic aorta, where hU-II was a potent spasmogen (pEC(50)=8.26+/-0.08) that evoked relatively little vasoconstriction (17+/-2% 60 mM KCl), vessels isolated from UT((-/-)) mice did not respond to hU-II. However, in contrast, the superior mesenteric artery isolated from both the genotypes did not contract in the presence of hU-II. Reactivity to unrelated vasoconstrictors (phenylephrine, endothelin-1, KCl) and endothelium-dependent/independent vasodilator agents (carbachol, sodium nitroprusside) was similar in the aorta and superior mesenteric arteries isolated from both the genotypes. 5 The present study is the first to directly link hU-II-induced vasoconstriction with the UT receptor. Deletion of the UT receptor gene results in loss of hU-II contractile action with no 'nonspecific' alterations in vascular reactivity. However, as might be predicted based on the limited contractile efficacy recorded in vitro, the contribution that hU-II and its receptor make to basal systemic haemodynamics appears to be negligible in this species.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12770952      PMCID: PMC1573852          DOI: 10.1038/sj.bjp.0705254

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

1.  Human urotensin II mediates vasoconstriction via an increase in inositol phosphates.

Authors:  O Saetrum Opgaard; H Nothacker; F J Ehlert; D N Krause
Journal:  Eur J Pharmacol       Date:  2000-10-13       Impact factor: 4.432

2.  Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey.

Authors:  S A Douglas; A C Sulpizio; V Piercy; H M Sarau; R S Ames; N V Aiyar; E H Ohlstein; R N Willette
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

3.  Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors.

Authors:  A Marchese; M Heiber; T Nguyen; H H Heng; V R Saldivia; R Cheng; P M Murphy; L C Tsui; X Shi; P Gregor
Journal:  Genomics       Date:  1995-09-20       Impact factor: 5.736

4.  Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries.

Authors:  A Stirrat; M Gallagher; S A Douglas; E H Ohlstein; C Berry; A Kirk; M Richardson; M R MacLean
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-02       Impact factor: 4.733

5.  Cardiostimulant effects of urotensin-II in human heart in vitro.

Authors:  F D Russell; P Molenaar; D M O'Brien
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

6.  Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14.

Authors:  Q Liu; S S Pong; Z Zeng; Q Zhang; A D Howard; D L Williams; M Davidoff; R Wang; C P Austin; T P McDonald; C Bai; S R George; J F Evans; C T Caskey
Journal:  Biochem Biophys Res Commun       Date:  1999-12-09       Impact factor: 3.575

7.  Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries.

Authors:  F E Bottrill; S A Douglas; C R Hiley; R White
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

8.  Human urotensin-II is a potent spasmogen of primate airway smooth muscle.

Authors:  D W Hay; M A Luttmann; S A Douglas
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

9.  Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1.

Authors:  J J Maguire; R E Kuc; A P Davenport
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

Review 10.  Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease.

Authors:  S A Douglas; E H Ohlstein
Journal:  Trends Cardiovasc Med       Date:  2000-08       Impact factor: 6.677

View more
  10 in total

1.  Urotensin II alters vascular reactivity in animals subjected to volume overload.

Authors:  Gregory S Harris; Robert M Lust; Laxmansa C Katwa; Christopher J Wingard
Journal:  Peptides       Date:  2010-08-17       Impact factor: 3.750

2.  Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity.

Authors:  Wei Song; John McDonald; Valeria Camarda; Girolamo Calo; Remo Guerrini; Erika Marzola; Jonathan P Thompson; David J Rowbotham; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-05       Impact factor: 3.000

3.  Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries.

Authors:  R T Bennett; R D Jones; A H Morice; C F C Smith; M E Cowen
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

4.  The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.

Authors:  David J Behm; Gerald Stankus; Christopher P A Doe; Robert N Willette; Henry M Sarau; James J Foley; Dulcie B Schmidt; Parvathi Nuthulaganti; James A Fornwald; Robert S Ames; David G Lambert; Girolamo Calo'; Valeria Camarda; Nambi V Aiyar; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

Review 5.  Role of urotensin II and its receptor in health and disease.

Authors:  John McDonald; Madura Batuwangala; David G Lambert
Journal:  J Anesth       Date:  2007-08-01       Impact factor: 2.078

6.  Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators.

Authors:  Douglas G Johns; Zhaohui Ao; Diane Naselsky; Christopher L Herold; Kristeen Maniscalco; Lea Sarov-Blat; Klaudia Steplewski; Nambi Aiyar; Stephen A Douglas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-30       Impact factor: 3.000

7.  Urotensin-II: a novel systemic hypertensive factor in the cat.

Authors:  David J Behm; Christopher P A Doe; Douglas G Johns; Kristeen Maniscalco; Gerald P Stankus; Alexandra Wibberley; Robert N Willette; Stephen A Douglas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-19       Impact factor: 3.000

Review 8.  Therapeutic potential of blockade of the urotensin II system in systemic hypertension.

Authors:  Henry Krum; Will Kemp
Journal:  Curr Hypertens Rep       Date:  2007-03       Impact factor: 4.592

Review 9.  Urotensin II in cardiovascular regulation.

Authors:  Fraser D Russell
Journal:  Vasc Health Risk Manag       Date:  2008

10.  Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2.

Authors:  Alexander A Goldberg; Kwang-Bo Joung; Asma Mansuri; Yujin Kang; Raquel Echavarria; Ljiljana Nikolajev; Yang Sun; Jane J Yu; Stephane A Laporte; Adel Schwertani; Arnold S Kristof
Journal:  Oncotarget       Date:  2016-09-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.